AVROBIO Inc Stock News

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive th

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Avrobio (AVRO), Dicerna Pharma (DRNA) and Daré Bioscience

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Avrobio ( AVRO – Research Report ), Dicerna Pharma ( DRNA – Research Report ) and Daré Bioscience

Upgrades * For Ultrapar Participacoes SA (NYSE: UGP), B of A Securities upgraded the stock from Neutral to Buy. For the fourth quarter, Ultrapar Participacoes had an EPS of \ No EPS Value , compared

AVROBIO, Inc. (Nasdaq:AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today shared an update on its response to the COVID-19 pand

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive th

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that members of its senior management team

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory

Analysts have clear opinions on AVRO. There are 4 analysts on the Wall offering 12 month price targets for Avrobio in the last 3 months. The average price target is $40.00 with a high forecast of $50.

Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 17) * BioNTech SE - ADR (NASDAQ: BNTX) * Regeneron P

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against AVROBIO, Inc.

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of AVROBIO, Inc. (NASDAQ: AVRO), resulting from allegations that

NEW YORK, NY / ACCESSWIRE / March 17, 2020 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of AVROBIO, Inc. ("AVROBIO" or the Company") (NASDAQ:AVRO).Inv

Mizuho Securities analyst Difei Yang maintained a Buy rating on Avrobio (AVRO) today and set a price target of $35.00. The company's shares closed last